Market Overview

Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018


Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that it will host a live conference
call and webcast at 8:30 a.m. ET on Tuesday, August 7, 2018 to report
its second quarter 2018 financial results and provide a corporate update.

To access the live conference call, please dial 866-595-4538 (domestic)
or 636-812-6496 (international), and refer to conference ID 8675009. A
webcast of the call will also be available on the Investors & Media
section of the Syros website at
An archived replay of the webcast will be available for approximately 30
days following the presentation.

About Syros Pharmaceuticals
Syros is pioneering the
understanding of the non-coding region of the genome to advance a new
wave of medicines that control expression of genes. Syros has built a
proprietary platform that is designed to systematically and efficiently
analyze this unexploited region of DNA in human disease tissue to
identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of
all cells, Syros' gene control platform has broad potential to create
medicines that achieve profound and durable benefit across a range of
diseases. Syros is currently focused on cancer and monogenic diseases
and is advancing a growing pipeline of gene control medicines. Syros'
lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2
clinical trial for genomically defined subsets of patients with acute
myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective
CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced
solid tumors. Led by a team with deep experience in drug discovery,
development and commercialization, Syros is located in Cambridge, Mass.

View Comments and Join the Discussion!